The next generation of non-invasive prenatal screening

Non-invasive prenatal testing (NIPT) analyzes cell-free DNA in a pregnant woman's blood to estimate the risk of fetal chromosomal abnormalities.

Panorama© uniquely distinguishes between fetal (placental) and maternal cell-free DNA, leading to fewer false positives and a more comprehensive basic panel compared with other screening methods.

Professional societies recognize the role of NIPT

ispd

Considers NIPT appropriate as primary screening test for all women.[1]

ACOG
THE AMERICAN CONGRESS OF OBSTETRICIANS AND GYNECOLOGISTS

Recommends providers educate patients on benefits and limitations of NIPT and other testing options.[2]

Panorama has validated performance in both high and average risk pregnancies

	Validation T21, T18, T13 and MX[3]		Clinical Outcomes T21, T18, T13 and MX[4] (Aneuploidy Incidence)
	Sensitivity	Specificity	PPV*
High Risk**	98.0% (98/100)	99.5% (389/391)	82.9% (2.4%)
Average Risk**	100% (5/5)	100% (469/469)	87.2% (1.0%)

* PPV = positive predictive value.

** For the purposes of calculating PPV, high risk was defined as women ≥35 years old at delivery, and average risk was defined as women <35 years old at delivery.

Panorama's advantages, when compared to traditional maternal serum screening

Higher sensitivity
for the conditions screened

Fewer false positives
fewer unnecessary invasive procedures[5]

More conditions included
more informative results

PAN-MD-FactSheetV7(6-4-16)NTL
NAT-8901332

Support every step of the way

1 SEAMLESS INTEGRATION into your workflow

- You can offer Panorama as early as 9 weeks gestation.

2 SAFE, EASY sample collection

- Your samples can be sent via a pre-packaged, post-marked kit to Natera.

3 ADVANCED TECHNOLOGY for results you can trust

- Panorama utilizes SNP-based sequencing and Natera's proprietary algorithms to deliver highly accurate and comprehensive results.

4 FAST, CLEAR REPORTING with support from our team

- Results come within 7-10 calendar days through Natera Connect with a release-to-patient function.
- Reports include risk score, PPV (if high risk) and fetal fraction to give you confidence in the results and the care plan for your patient.

Commonly Asked Questions

WHAT CONDITIONS DOES PANORAMA SCREEN FOR?

Whole Chromosome Conditions
- Trisomies 21, 18 and 13
- Monosomy X
- Sex chromosome trisomies
- Triploidy
- Complete molar pregnancy

Optional
- 22q11.2 deletion
- Angelman
- Cri-du-chat
- 1p36 deletion
- Prader-Willi
- Fetal sex

HOW DO I REQUEST MORE TEST KITS?

Panorama collection kits are provided to the clinic at no charge and can be stored on-site.

To order a Panorama Prenatal Screen collection kit

CLICK: via Natera Connect
VISIT: NateraOrder.com
CALL: +1 (650) 249.9090
EMAIL: support@natera.com
CONTACT: your Natera representative

natera™ Conceive. Deliver.
panorama™ natera prenatal screen | horizon™ natera carrier screen | spectrum™ natera preimplantation genetics (PGS/PGD) | anora™ natera miscarriage test (POC) | constellation™ natera software platform

natera | 201 Industrial Road, Suite 410 | San Carlos, CA 94070 USA | +1 (650) 249.9090 | Fax +1 (650) 730.2272

panorama™
natera prenatal screen

Highly accurate, comprehensive **results you can trust**

The Panorama® Prenatal Screen identifies:

Whole Chromosome Conditions
- Trisomy 21, 18, 13
- Monosomy X
- Sex chromosome trisomies
- Triploidy
- Complete molar pregnancy

Optional
- 22q11.2 deletion syndrome
- Additional microdeletion syndromes
- Fetal sex

natera™
Conceive. Deliver.

A superior first-line screening test for all women

Panorama screens for more chromosomal abnormalities, with greater accuracy

Compared to First Trimester Screening, Panorama has higher sensitivity and lower false positive rate for the conditions screened.

HIGHLY ACCURATE AND COMPREHENSIVE SCREENING

Condition	First Trim. Screen[6]	Panorama[3,7]
	Sensitivity False Positive Rate	**Sensitivity** False Positive Rate
Trisomy 21 *Down Syndrome*	**79%** 5%	**>99.9 (83/83)** **0%**
Trisomy 18 *Edwards Syndrome*	**80%** 0.3%	**96.4% (27/28)** <0.1%
Trisomy 13 *Patau Syndrome*	**50%** 0.3%	**>99% (13/13)** 0%
Monosomy X *Turner Syndrome*	*Does not screen for*	**92.9% (13/14)** <0.1%
Triploidy	*Does not screen for*	**>99% (8/8)**
Female	*Does not determine*	**>99.9% (469/469)** 0%
Male	*Does not determine*	**>99.9% (533/533)** 0%
Optional Microdeletion Syndromes		
22q11.2 deletion *DiGeorge syndrome*	*Does not screen for*	**95.7% (45/47)**
Additional microdeletions*	*Does not screen for*	**93.8 - >99%**

*Additional microdeletions include: Angelman, Cri-du-chat, 1p36 deletion & Prader-Willi

Higher PPV = less anxiety for patients

Consider **100** **pregnant women** that receive a **"HIGH RISK"** result for Trisomy 21...

First Trimester Screening[6]

3 will be **true positive**

97 will be **false positive** and referred for unnecessary invasive testing

Panorama[4]

91 will be **true positive**

9 will be **false positive**

Non-invasive method with more informative results

Discussing NIPT with your patients, per ACOG guidelines[2]



"Testing for chromosome abnormalities is optional."

*"If you would like to know the risk of your baby having a chromosome abnormality, **screening options** are available."*

*"If you want to know for sure about chromosome abnormalities, you can opt for **diagnostic testing.**"*

Least Information → Most Information

	No testing	Traditional Serum Screen	NIPT	CVS/AMNIO
BENEFITS	- Less anxiety for women who may worry about testing - No difficult decisions to make in case of abnormal results	- Non-invasive - If performed in 2nd trimester, screens for certain birth defects like spina bifida	- Non-invasive - Screens for more conditions* - Higher sensitivity & positive predictive value* - Most women receive low risk results,[4] thereby reducing anxiety - Screen as early as 9 weeks	- Definitive results - More comprehensive than NIPT or serum screening - Ability to plan for baby's care in case of abnormal results
LIMITATIONS	- Inability to plan medically, financially & emotionally - Missed opportunity to engage with specialists & community support resources	- Not diagnostic - Limited to Trisomy 21, 18 and 13 - Lower sensitivity, higher false positive rate and lower positive predictive value than NIPT	- Not diagnostic; false positives and false negatives do occur - Does not screen for all chromosome abnormalities - May not be able to report results in a small number of patients	- Invasive; small risk of miscarriage - Amnio results not available until 2nd trimester - Possible results of uncertain significance

*Compared to serum screening

High accuracy through SNP-based NIPT methodology

Panorama targets single nucleotide polymorphisms (SNPs) in cell-free DNA



Unique clinical benefits due to SNP-based methodology

REDUCES FALSE POSITIVES COMPARED TO OTHER NIPT METHODS

VANISHING TWIN
Only Panorama can identify a vanishing twin, which may contribute to >15% of false positive results with other NIPTs.[8,9]

>99.9% FETAL SEX ACCURACY[3]
No incorrect gender calls in validation studies. Less anxiety and unnecessary work-up for patients.

MATERNAL ABNORMALITIES
Only Panorama minimizes the chance that a maternal abnormality leads to a false positive result. This is a significant cause of false positives when using other NIPTs.[10]

IDENTIFIES CONDITIONS ASSOCIATED WITH COMPLICATIONS FOR MOM

COMPLETE MOLAR PREGNANCY
Only Panorama identifies complete molar pregnancy, which can be associated with preeclampsia, hemorrhage, and gestational trophoblastic neoplasia, and rarely, metastatic choriocarcinoma.[11]

TRIPLOIDY
Only Panorama identifies triploidy, which is often associated with stillbirth, severe birth defects and preeclampsia.[8,12]

Measuring fetal fraction is critical for high-confidence NIPT results

- √ **NIPTs target fetal (placental) DNA for determining fetal risk of chromosomal abnormalities**
- √ **ACOG emphasizes the importance of fetal fraction as "essential for accurate test results"[2]**
- √ **Failure to measure fetal fraction can correlate to false negative results[13]**

Extensive clinical experience around the world[14]

>500,000 . . . Panorama cases have been reported.

1 out of 5 . . . OBGYN/MFM physicians have ordered Panorama in the US alone.

60+ . . . countries around the world have Panorama commercially available.

References: available at http://www.panoramatest.com/en/FactSheetReferences2